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A xanthine amine congener (XAC), an amine-functionalized erivative of 1,3-dipropyl-8_phenyIxanthine, 
is an antagonist ligand for A2 adenosine receptors of human platelets. XAC inhibited 5’-N-ethylcarbox- 
amidoadenosine (NECA)-induced stimulation of adenylate cyclase activity with a KB of 24 nM. [3H]XAC 
exhibits saturable, specific binding with a I& of 12 nM and a B,,, of 1.1 pmol/mg protein at 37°C. [3H]XAC 
binding in platelets is the first example of labeling of A2 adenosine receptors in which the potencies of ade- 
nosine agonists and antagonists in inhibiting binding are commensurate with their potencies at these recep- 
tors in functional studies. Furthermore, [3H]XAC is the first antagonist radiohgand with high affinity at 
A2 adenosine receptors. 
Adenosine receptor Platelet Xan thine 
1. INTRODUCTION 
A variety of radioligands have been developed 
for the Al adenosine receptors that mediate inhibi- 
tion of adenylate cyclase: such ligands have been 
extensively used in investigation of Al receptors 
(reviews [1,2]). Radioligands for the A2 adenosine 
receptors that mediate stimulation of adenylate 
cyclase have not proven entirely satisfactory. In 
striatal membranes, 5’-N-[3H]ethylcarboxamido- 
adenosine ([‘HINECA) appears to bind to both Al 
and A2 adenosine receptors, and strategies for 
elimination of Al receptor binding have been 
developed [3]. In peripheral tissues, binding 
studies with [3H]NECA have not been proven 
satisfactory, particularly with respect to structure- 
activity profiles for adenosine antagonism by 
adenosine analogs and xanthines [2]. 
1,3-[3H]Diethyl-8-phenylxanthine U3HlDW 
has been the only antagonist radioligand for the 
study of adenosine receptors [4]. Based on a 
binding study with guinea pig brain, the suggestion 
has been made that [3H]DPX may label A2 
adenosine receptors [4]. This appears unlikely, 
since M-substituted adenosine analogs were very 
weak and compounds without intrinsic activity at 
adenosine receptors were relatively potent in com- 
peting for [3H]DPX binding [4]. Thus, a direct 
characterization of A2 adenosine receptors with an 
antagonist radioligand has still not been achieved, 
and even for Al receptors [3H]DPX is not entirely 
satisfactory. 
A ‘functionalized congener’ approach to 
adenosine receptor ligands has been developed 
[5,6]. In this approach 1,3-dipropyl-8-phenylxan- 
thine was modified to provide a p-carboxy- 
methyloxy function for covalent attachment to 
amines, amino acids and oligopeptides [5,6]. One 
potent analog, a 1,3_dipropylxanthine amine con- 
gener (XAC), has been tritiated to high specific ac- 
tivity (103 Ci/mmol). [3H]XAC binds with & 
values of 0.17 and 1.2 nM to Al adenosine recep- 
tors of calf and rat brain, respectively [7]. It 
represents the most satisfactory antagonist 
radioligand for the study of Al adenosine recep- 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/86/%3.50 0 1986 Federation of European Biochemical Societies 269 
Volume 199, number 2 FEBS LETTERS April 1986 
tors. Here, [3H]XAC was used as a radioligand for 
the A2 adenosine receptors in human platelets. 
2. MATERIALS AND METHODS 
Human platelet membranes were prepared as in 
[8]. Adenylate cyclase was assayed essentially as 
described [8]. Briefly stated, the medium contained 
0.1 mM [a-32P]ATP (0.3 &i/tube), 1 pM GTP, 
1 mM MgC12, 0.1 mM cyclic AMP, 1 pg/ml 
adenosine deaminase, 0.1 mM rolipram (4-(3-cy- 
clopentyloxy-4-methoxyphenyl)-2-pyrrolidinone, 
ZK 62,71 l), 1 mM EGTA, 5 mM creatine 
phosphate as the Tris salt, 0.4/1g/ml creatine 
kinase, 2 mg/ml bovine serum albumin and 
50 mM Tris-HCl, pH 7.4, in a total volume of 
100~1. Incubations were initiated by the addition 
of 5- 15 pg membrane protein and were conducted 
for 10 min at 37°C. Reactions were stopped by the 
addition of 0.4 ml of 125 mM zinc acetate and 
0.5 ml of 144 mM NazCO3. Cyclic AMP was 
purified as described in [8]. 
180 
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The binding of [3H]XAC to human platelet 
membranes was measured in a total volume of 
1 ml containing 50 mM Tris-HCl, pH 7.4, 
0.1 pg/ml adenosine deaminase and approx. 
100-200 pg membrane protein. In competition ex- 
periments the radioligand was present in a final 
concentration of 1 nM. Other substances were 
added as indicated. Incubation was carried out at 
37°C for 90 min. All assays were done in triplicate. 
Bound and free radioligand were separated by 
filtering the assay volume through Whatman 
GF/B glass-fiber filters that had been treated with 
0.3% polyethylene imine for 90 min as described 
by Bruns et al. [9]. The filters were washed twice 
with 5 ml ice-cold incubation buffer. Nonspecific 
binding of t3H]XAC was determined in the 
presence of 5 mM theophylline. 
Synthesis and purification of ‘H-labeled 8-( 4- 
[([ ((2 - aminoethyl)amino)carbonyl]methyl)oxy] - 
phenyl ) -1,3_dipropylxanthine (t3H]XAC) with a 
specific activity of 103 Ci/mmol are described 
elsewhere [7]. Other compounds were synthesized 
log,,, [XACI IMI 
cb4’ I I I 1 I 
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Fig.1. Stimulation of adenylate cyclase activity of human platelet membranes by NECA in the absence (M) and 
presence of XAC (2 nM, H ; 20 nM, ti ; 200 nM, H). Adenylate cyclase activity was determined at 37°C 
for 90 min. Right: Schild plot of the same data with the concentration ratio (CR) of the EC.50 values for NECA in the 
presence and absence of XAC vs the XAC concentration (slope, 1.05; r = 0.9993). EGO values for NECA: 0.255 pM 
in the absence and 0.27, 0.46 and 2.29 PM in the presence of 2, 20 and 200 nM XAC, respectively. Values are means 
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of a typical experiment done in triplicate. 
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as in [5-71. Materials and chemicals were from 
standard sources as described [5,7]. 
EC50 and ICSO values were obtained from 
concentration-response curves by linear regression 
after logit-log transformation. I& values were 
transformed into Kr values according to Cheng and 
Prusoff [lo]. Slope factors of inhibition curves 
(nn) were calculated from indirect Hill plots. 
3. RESULTS 
The potency of XAC as an antagonist at A2 
adenosine receptors of human platelets was deter- 
mined vs the NECA-stimulated adenylate cyclase 
activity in membranes. In human platelets, NECA 
has been shown to be a potent agonist at A2 recep- 
tors that mediate inhibition of aggregation via an 
activation of adenylate cyclase [8,11]. NECA 
stimulates adenylate cyclase activity about 4-fold 
over basal values with an EGO of 0.255 pM (fig. 1). 
XAC shifted the concentration-response curve of 
NECA in a concentration-dependent manner to 
the right without changing the slope or the degree 
of stimulation by NECA (fig.1) suggesting com- 
14 
petitive antagonism. The dissociation constant, 
KB, for XAC, calculated from the Schild plot, was 
24 nM as shown in the right panel of fig.1. The 
slope of the line near unity confirms the com- 
petitive antagonism between NECA and XAC. 
Radioligand binding experiments with tritiated 
XAC were performed at 37°C. A typical satura- 
tion experiment is shown in fig.2. Specific 
[3H]XAC binding is saturable with a binding 
capacity (Bma,) of 1.1 pmol/mg protein. The 
Scatchard plot of the data is linear, indicating a 
homogeneous population of noncooperative 
binding sites with a Kd of 12 nM. Nonspecific 
binding determined in the presence of 5 mM 
theophylline was very high and amounted to about 
75% of total binding at Kd. The same amount of 
nonspecific binding was obtained in the presence 
of 1 mM NECA. At 4”C, similar Kd and Bmax 
values were obtained, and nonspecific binding 
amounted to 60% of total binding at Kd (not 
shown). 
Other known agonists and antagonists at 
adenosine receptors competitively displaced 
specific [3H]XAC binding to platelet membranes 
(fig.3, table 1). The competition curves are 
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Fig.2. Saturation of [3H]XAC binding to human platelet membranes. Specific (W-O) and nonspecific (m) 
binding were determined for 90 min at 37°C. Values are means of a typical experiment done in triplicate. Right: 
Scatchard plot of the same data. &, 12 nM; B,,,, 1.1 pmol/mg protein. 
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Fig.3. Competition for 13H]XAC binding to human platelet membranes. Binding of 1 nM [‘H]XAC was measured for 
90 min at 37*C. Sfope factors: 0.94 for XAC (M), 0.91 for NECA (t-*), 0.97 for 8-phenyitheophyIline 
(w), 0.99 for R-PIA (H) and 0.91 for theophylline (A--J). Values are means of a typical experiment done 
in triplicate. 
Table 1 
Competition for [3H]XAC binding to human platelet 
membranes 
Compound 4 @M) 
1,3-Dipropyl-&(H2N(CH2)2NHCOCHr- 
O*phenyl)xanthine (XAC) 0.017 
1,3-Diethyl-8-phenylxanthine (DPX) 0.19 
5 ’ -N-Ethylcarboxamidoadenosine 0.33 
1,3-Dipropyl-8-phenylxanthine 1.0 
8Phenyltheophylline 1.7 
1,3-Dipropyl-8-~-HO2CCHzO-phenyl)- 
xanthine (XCC) 1.8 
1,3-Dipropyl-8@-sulfophenyl)xanthine 2.4 
~-R-Phenylisopropyladenosiae (R-PIA) 5.7 
8-@Sulfophenyl)theophylline 7.2 
Theophylline 29 
Caffeine 51 
ATP > loo (25%) 
Adenine > 100 (19%) 
Inosine > loo (l@Io) 
Binding of 1 nM [3H]XAC was measured for 90 min at 
37°C. K, values are means of 2 experiments done in 
triplicate. For Ki values above 100/1M, the percentage 
inhibition of [‘H]XAC binding at 1OOpM is given in 
parentheses 
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monophasic with slope factors near unity. XAC 
itself was the most potent inhibitor of r3H]XAC 
binding with a Ki value of 17 nM. This value is in 
good agreement with the Kd values derived from 
the saturation experiments with [3H]XAC. DPX 
was about IO-fold less potent than XAC, but about 
5-fold more potent than 1,3-dipropyl&phenyl- 
xanthine. The carboxylic acid congener (XCC) and 
the p-sulfo derivative of the latter compound were 
as potent as 8-phenyltheophylline in competing for 
[3H]XAC-binding sites. Theophylline and caffeine 
have Ki values of 29 and 51 PM, respectively, 
whereas ATP, adenine and inosine were inactive at 
(3H]XAC-binding sites. The agonist NECA has a 
Ki of 0.33 pM, which is in good agreement with the 
EC50 value for the stimulation of adenylate cyclase 
activity in these membranes. R-PIA was about 
20-fold less potent than NECA as an inhibitor of 
[‘H]XAC binding and is IO-fold less potent than 
NECA in stimulation of adenylate cyclase activity. 
4. DISCUSSION 
Several attempts have been made to characterize 
A2 adenosine receptors in radioligand-binding 
studies. r3H]NECA has been used often as an 
agonist radioligand for A2 adenosine receptors 
[12-151. However, the binding characteristics of 
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[3H]NECA to membranes containing only A2 
receptors are not fully consonant with that ex- 
pected of A2 receptors, since p-substituted 
adenosine analogs, which do activate adenylate 
cyclase in these membranes, are weak or inactive as 
antagonists of [3H]NECA binding [12-151. Fur- 
thermore, antagonists like DPX and 8-phenyl- 
theophylline, which are potent inhibitors of 
NECA-induced cyclic AMP accumulation or 
NECA-stimulated adenylate cyclase activity, did 
not compete for [‘HINECA-binding sites 
[13,15,16]. At least in peripheral tissues, therefore, 
the results with [3H]NECA have not been 
satisfactory. 
The antagonist radioligand [3H]DPX has been 
reported to label A2 adenosine receptors in guinea 
pig brain membranes [4]. Again, several discrepan- 
cies in the structure-activity profile were observed. 
Compounds that are neither agonists nor an- 
tagonists at A2 receptors in brain, such as 
8-bromoadenosine, competed for [3H]DPX 
binding, whereas the potent receptor against 5 ’ -IV- 
cyclopropylcarboxamidoadenosine was a very 
weak displacer o,f [‘H]DPX binding [4]. Therefore, 
the nature of the [3H]DPX-binding sites in guinea 
pig brain remains unclear [2,4]. In addition, 
[3HEDPX has several shortcomings: it has only a 
low affinity for adenosine receptors in most tissues 
and a relatively low specific activity. 
Recently, we have introduced a tritiated xan- 
thine amine congener ([3H]XAC) as new an- 
tagonist radioligand for adenosine receptors [7]. 
[3H]XAC overcomes many of the limitations of the 
[3H]DPX radioligand. The & value for [3H]XAC 
binding to Al receptors in rat brain membranes is 
50-fold lower than that of [‘H]DPX [7], and the 
specific activity is g-fold higher than that of 
[3H]DPX. In addition to the usefulness of 
[3H]XAC as a radioligand for Al receptors, the 
present study demonstrates that [3H]XAC is also 
useful for labeling of A2 adenosine receptors, 
XAC has a KB value of 24 nM for the antagonism 
of NECA-induced stimulation of adenylate cyclase 
activity in human platelet membranes. Thus, XAC 
is the most potent xanthine antagonist at A2 
adenosine receptors yet reported. 
In platelet membranes, [3H]XAC exhibits 
saturable, specific binding with a & of 12 nM, 
which is about 2-fold lower than the KB deter- 
mined in cyclase experiments. The Ki value of 
XAC for inhibition of [3H]XAC binding is in good 
agreement with the Kd value from the saturation 
experiments and the KB value from the cyclase ex- 
periments. Several xanthines compete for 
[3H]XAC binding in the known order of potency. 
The Ki values of these xanthines are in good agree- 
ment with the KB values for antagonism of NECA- 
induced adenylate cyclase stimulation in the same 
membrane preparation [la, 171. Only the Ki value 
for theophylline is 2-3-fold higher than that deter- 
mined in cyclase and aggregation studies [ 16,171. 
The potencies of the adenosine agonists NECA 
and R-PIA in inhibiting [3H]XAC binding are 
similar to the EC50 values for the stimulation of 
adenylate cyclase activity [8]. In contrast to the 
results with [3H]NECA binding in platelets [14], 
therefore, the profile of agonists and antagonists 
for the inhibition of t3H]XAC binding is commen- 
surate with the data from functional studies like 
adenylate cyclase and aggregation [8,16,17]. 
A relative high level of filter binding was evident 
with [3H]XAC. The problem was solved in part by 
pretreatment of the glass-fiber filters with 
polyethylene imine according to Bruns et al. [9]. 
The filter binding is the main reason for the high 
nonspecific binding as shown in the saturation ex- 
periment (fig.2). A further reduction in filter 
binding should permit the use of J3H]XAC for 
more detailed studies on A2 adenosine receptors in 
other tissues. 
ACKNOWLEDGEMENT 
One of the authors (D.U.) is on leave from the 
Pharmakologisches Institut der Universitat 
Heidelberg with support of the Deutsche 
Forschungsgemeinschaft (Uk 4/l-l). 
REFERENCES 
111 
121 
[31 
141 
PI 
Daly, J.W. (1982) J. Med. Chem. 25, 197-207. 
Daly, J.W. (1985) in: Adenosine: Receptors and 
Modulation of Cell Function (Stefanovich, V. et al. 
eds) pp.31-46, IRL Press, Washington, DC. 
Yeung, S.-M.H. and Green, R.D. (1984) Naunyn- 
Schmiedeberg’s Arch. Pharmacol. 325, 218-225. 
Bruns, R.F., Daly, J. W. and Snyder, S.H. (1980) 
Proc. Natl. Acad. Sci. USA 77, 5547-5551. 
Jacobson, K.A., Kirk, K.L., Padgett, W.L. and 
Daly, J.W. (1985) J. Med. Chem. 28, 1334-1340. 
273 
Volume 199, number 2 FEBS LETTERS April 1986 
[6] Jacobson, K.A., Kirk, K.L., Padgett, W.L. and 
Daly, J.W. (1986) Mol. Pharmacol., in press. 
[7] Jacobson, K.A., Ukena, D., Kirk, K.L. and Daly, 
J.W. (1986) Proc. Natl. Acad. Sci. USA, in press. 
[8] Ukena, D., Boehme, E. and Schwabe, U. (1984) 
Naunyn-Schmiedeberg’s Arch. Pharmacol. 327, 
36-42. 
[9] Bruns, R.F., Lawson-Wendling, K. and Pugsley, 
T.A. (1983) Anal. Biochem. 132, 74-81. 
[lo] Cheng, Y.C. and Prusoff, W.H. (1973) Biochem. 
Pharmacol. 22, 3099-3108. 
[ll] Cusack, N.J. and Hourani, S.M.O. (1981) Br. J. 
Pharmacol. 72, 443-447. 
[12] Schiitz, W., Tuisl, E. and Kraupp, 0. (1982) 
Naunyn-Schmiedeberg’s Arch. Pharmacol. 319, 
34-39. 
[13] Schlitz, W., Steuerer, G. and Tuisl, E. (1982) Eur. 
J. Pharmacol. 85, 177-184. 
[14] Htittemann, E., Ukena, D., Lenschov, V. and 
Schwabe, U. (1984) Naunyn-Schmiedeberg’s Arch. 
Pharmacol. 325, 226-233. 
[15] Ukena, D., Schirren, C.G., Klotz, K.-N. and 
Schwabe, U. (1985) Naunyn-Schmiedeberg’s Arch. 
Pharmacol. 331, 310-316. 
[16] Ukena, D., Boehme, E. and Schwabe, U. (1985) in: 
Adenosine: Receptors and Modulation of Cell 
Function (Stefanovich, V. et al. eds) pp.343-349, 
IRL Press, Washington, DC. 
[ 171 Ukena, D., Daly, J.W., Kirk, K.L. and Jacobson, 
K.A. (1986) Life Sci. 38, 797-807. 
274 
